
-
Trump says bringing $15 bn lawsuit against New York Times
-
Israel sets Gaza 'on fire' as Rubio warns days left for deal
-
Phillies clinch first MLB division by beating Dodgers
-
'Nothing here': Lack of jobs forces young Nepalis abroad
-
Rubio asks Qatar to stay as mediator after Israeli strike
-
Trump set for unprecedented second UK state visit
-
Lower US tariffs on Japan autos kick in
-
Revamped Bayern face early test as Chelsea come to town
-
Papua New Guinea, Australia to vow mutual defence in new treaty
-
Malawi election a battle of two presidents
-
Asian markets rise as traders prepare for expected US rate cut
-
Malawi votes in a rematch between two presidents as economic crisis bites
-
Australia says social media ban will not age test all users
-
Poland's Nawrocki talks drone defence in Paris and Berlin
-
Trump's fossil fuel agenda challenged in youth climate suit
-
PSG fear impact of injuries as they put Champions League title on the line
-
US Senate confirms Trump aide to Fed as politics loom over rate meeting
-
Papua New Guinea, Australia will commit to mutual defence
-
Trash, mulch and security: All jobs for troops in Washington
-
Tocvan Announces Commencement Of Field Work And Airborne Magnetics Survey At Gran Pilar Gold Silver Project; Drilling And Trenching Prep Accelerate Discovery & Pilot Mine Production
-
NFL legend Brady to play in March flag football event at Riyadh
-
Lower US tariffs on Japan autos to take effect Tuesday
-
US strikes second alleged Venezuelan drug boat as tensions mount
-
Protesting Peru residents block trains to Machu Picchu
-
US strikes another alleged Venezuelan drug boat as tensions rise
-
White House vows to take on left-wing 'terror' movement after Kirk killing
-
Brazil's Amazon lost area the size of Spain in 40 years: study
-
US Senate poised to advance Trump aide's appointment at Fed
-
Sri Lanka survive Hong Kong scare for four wicket Asia Cup win
-
Arab, Muslim leaders urge review of Israel ties after Qatar attack
-
Mbappe 'not anxious' over Champions League goal as Bellingham returns
-
Huge pot of Nigerian jollof rice sets Guinness record
-
Heartbreak will help Arsenal's Champions League charge: Arteta
-
Europe stumped by Trump demands over Russia sanctions
-
Cycling fears spread of race-halting protests after Vuelta chaos
-
US, China reach 'framework' deal on TikTok ownership
-
'With our fists if necessary': Venezuelans prepare to defend homeland against potential US invasion
-
Duplantis thrives on Tokyo energy to break world record again
-
Ex-France defender Umtiti calls time on club career
-
One in six US parents rejecting standard vaccine schedule: poll
-
Sheffield Utd appoint Wilder for third managerial spell
-
UAE hammer Oman in Asia Cup to keep Super Four hopes alive
-
Activists on trial as France debates right to die
-
Duplantis reaches new heights, Beamish makes Kiwi history at worlds
-
Frank relishing Champions League debut with Spurs
-
Spanish PM calls for Israel to be barred from international sport
-
UK aristocrat, partner get 14 years for baby daughter's manslaughter
-
US says 'framework' deal with China on TikTok ownership
-
Shootings 'unjustified' in Bloody Sunday killings, Belfast court hears
-
Three French women accused of IS links go on trial

RFK Jr panel votes against ingredient targeted by anti-vaxxers
A newly appointed US medical panel voted Thursday to oppose the use of a vaccine ingredient long targeted by Health Secretary Robert F. Kennedy Jr. over debunked claims it causes autism.
Thimerosal, a preservative that prevents bacterial and fungal contamination in multidose vials, has been extensively studied, with authorities including the World Health Organization finding no evidence of harm beyond minor injection-site reactions.
Though thimerosal is now rarely used in US vaccines, its inclusion on the Advisory Committee on Immunization Practices' agenda alarmed experts, who say the move has effectively embedded anti-vaccine talking points into national policy.
Kennedy -- who spent decades spreading vaccine misinformation before becoming President Donald Trump's top health official -- abruptly fired all 17 ACIP members earlier this month, accusing them of conflicts of interest.
Across three votes, his new handpicked panelists recommended that thimerosal be removed from influenza vaccines for children, pregnant women and finally all adults.
Cody Meissner, a professor of pediatrics at Dartmouth University and the lone voice of dissent, said: "The risk from influenza is so much greater than the nonexistent risk as far as we know from thimerosal," adding that he was worried about the decision's global impact.
Although 96 percent of US flu vaccines in the 2024-2025 season did not contain thimerosal, the preservative remains important globally, particularly in multidose vials that must be punctured repeatedly, raising the risk of contamination.
Thimerosal contains an artificial form of mercury called ethylmercury that is cleared from the body far more quickly than the form of the substance found in nature.
US manufacturers voluntarily removed it from most pediatric vaccines in 2001.
- 'Platform for anti-vaccine talking points' -
"The fact that it's being brought up again -- something that's already been adjudicated -- shows how the ACIP is becoming a platform for anti-vaccine talking points to come back to life long after most of us thought they'd been put to rest," Amesh Adalja, an infectious disease specialist at Johns Hopkins University, told AFP.
Ahead of the vote, Lyn Redwood, a nurse and former leader of the anti-vaccine group Children's Health Defense, which Kennedy once chaired, was invited to present arguments against thimerosal.
A previous version of her slideshow, which was posted online before the meeting, was removed without explanation after it was found to contain a fabricated citation, likely the result of an AI hallucination.
The Centers for Disease Control and Prevention had prepared a rebuttal to Redwood's presentation, but it was mysteriously removed from the meeting website.
Robert Malone, a new panel member known for spreading misinformation during the Covid-19 pandemic, including promoting the antiparastic drug ivermectin to treat the virus, later said the CDC document had not been approved by the Office of the Secretary.
Earlier in the meeting, the same panel voted to recommend a new antibody treatment against RSV, a common respiratory illness and the leading cause of infant hospitalization in the United States.
Clesrovimab, recently approved by the Food and Drug Administration, is administered as a single shot to newborns and young babies entering their first respiratory syncytial virus season.
Marketed as Enflonsia by Merck, it was shown in clinical trials to significantly reduce RSV infections and hospitalizations among infants.
L.Davis--AMWN